60岁及以上成年人接种第四剂BNT162b2疫苗前后的体液和T细胞反应
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years.
作者信息
Bar-Haim Erez, Eliakim-Raz Noa, Stemmer Amos, Cohen Hila, Elia Uri, Ness Asaf, Awwad Muhammad, Ghantous Nassem, Moskovits Neta, Rotem Shahar, Stemmer Salomon M
机构信息
Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel.
Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel.
出版信息
J Clin Med. 2022 May 8;11(9):2649. doi: 10.3390/jcm11092649.
Abstract
Both humoral and cellular anamnestic responses are significant for protective immunity against SARS-CoV-2. In the current study, the responses in elderly people before and after a fourth vaccine dose of BNT162b2 were compared to those of individuals immunized with three vaccine doses. Although a boost effect was observed, the high response following the third administration questions the necessity of an early fourth boost.
摘要
体液和细胞记忆反应对于针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的保护性免疫均具有重要意义。在本研究中，将老年人在接种第四剂BNT162b2疫苗前后的反应与接种三剂疫苗的个体的反应进行了比较。尽管观察到了加强效果，但第三次接种后的高反应性让人质疑早期进行第四次加强的必要性。
相似文献
1
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years.60岁及以上成年人接种第四剂BNT162b2疫苗前后的体液和T细胞反应
J Clin Med. 2022 May 8;11(9):2649. doi: 10.3390/jcm11092649.
2
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.短期来看，以色列 60 岁及以上人群中，4 剂与 3 剂 BNT162b2 疫苗的相对有效性：回顾性、阴性检测、病例对照研究。
BMJ. 2022 May 24;377:e071113. doi: 10.1136/bmj-2022-071113.
3
Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.在有和没有SARS-CoV-2感染史且先前已接种两剂BBIBP-CorV加BNT162b2疫苗的医护人员中接种第四剂mRNA-1273后的体液免疫反应。
Vaccines (Basel). 2023 Apr 25;11(5):894. doi: 10.3390/vaccines11050894.
4
Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection.BNT162b2 mRNA 疫苗接种和 COVID-19 感染后的特异性免疫反应。
Front Immunol. 2023 Oct 17;14:1271353. doi: 10.3389/fimmu.2023.1271353. eCollection 2023.
5
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.接种 BNT162b2 双剂疫苗后第三剂 BNT162b2 与 ChAdOx1 对癌症患者的体液和细胞免疫对 SARS-CoV-2 的反应。
Clin Cancer Res. 2023 Feb 1;29(3):635-646. doi: 10.1158/1078-0432.CCR-22-2185.
6
Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.在未感染和既往感染个体中，接受 BNT162b2 疫苗第一、第二和第三剂后，针对 SARS-CoV-2 的特异性抗体反应的差异：一项在医护人员中进行的为期 1 年的观察性研究。
Front Immunol. 2022 May 27;13:876533. doi: 10.3389/fimmu.2022.876533. eCollection 2022.
7
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.在英国，使用不同的第三剂 COVID-19 疫苗接种方案进行同源和异源加强免疫后免疫应答的持久性：COV-BOOST 试验的 8 个月分析。
J Infect. 2023 Jul;87(1):18-26. doi: 10.1016/j.jinf.2023.04.012. Epub 2023 Apr 20.
8
Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.针对第三剂 BNT162b2 COVID-19 疫苗的细胞和体液免疫反应 - 一项前瞻性观察研究。
Front Immunol. 2022 Jul 1;13:896151. doi: 10.3389/fimmu.2022.896151. eCollection 2022.
9
Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.奥密克戎 BA.1 特异性 T 细胞应答在香港接种科兴或辉瑞疫苗的成年人中的观察性队列研究。
Lancet Microbe. 2023 Jun;4(6):e418-e430. doi: 10.1016/S2666-5247(23)00006-X. Epub 2023 Apr 20.
10
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.一种自我扩增 RNA COVID-19 疫苗（ARCT-154）与 BNT162b2 mRNA COVID-19 疫苗加强针的免疫原性和安全性：一项双盲、多中心、随机、对照、3 期、非劣效性试验。
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
引用本文的文献
1
Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination.血未结合胆红素和他克莫司是肾移植受者 SARS-CoV-2 灭活疫苗接种后特异性细胞免疫的负预测因子。
Sci Rep. 2023 May 4;13(1):7263. doi: 10.1038/s41598-023-29669-8.
2
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.免疫功能低下患者接种第四剂 SARS-CoV-2 mRNA 疫苗后对奥密克戎的中和抗体强调了需要额外加强针。
Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023.
3
Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain.在西班牙一家大学医院中，mRNA-1273、BNT162b2 和 ChAdOx1 疫苗接种后 9 个月的体液和细胞免疫应答。
Sci Rep. 2022 Oct 7;12(1):15606. doi: 10.1038/s41598-022-19537-2.
4
Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern.无症状或有症状的新冠病毒感染加上疫苗接种可增强对关注变异株的适应性免疫力。
iScience. 2022 Oct 21;25(10):105202. doi: 10.1016/j.isci.2022.105202. Epub 2022 Sep 23.
5
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy.第二剂BNT162b2加强针可恢复多发性骨髓瘤患者的新冠病毒体液免疫反应，但接受抗BCMA治疗的患者除外。
Hemasphere. 2022 Jul 29;6(8):e764. doi: 10.1097/HS9.0000000000000764. eCollection 2022 Aug.
本文引用的文献
1
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.在以色列，第四剂 BNT162b2 对奥密克戎的保护作用。
N Engl J Med. 2022 May 5;386(18):1712-1720. doi: 10.1056/NEJMoa2201570. Epub 2022 Apr 5.
2
T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.接种抗 COVID-19 BNT162b2 疫苗后，T 细胞的反应仍然可以针对关注的 SARS-CoV-2 奥密克戎 B.1.1.529 变体。
Viruses. 2022 Feb 8;14(2):347. doi: 10.3390/v14020347.
3
SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.SARS-CoV-2 疫苗接种可诱导能够交叉识别 Alpha 到奥密克戎变体的免疫 T 细胞记忆。
Cell. 2022 Mar 3;185(5):847-859.e11. doi: 10.1016/j.cell.2022.01.015. Epub 2022 Jan 24.
4
Boosting immunity to COVID-19 vaccines.增强对新冠疫苗的免疫力。
Nat Med. 2021 Nov;27(11):1874-1875. doi: 10.1038/s41591-021-01560-x.
5
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
6
Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.≥60 岁成年人接种第三剂 SARS-CoV-2 BNT162b2 疫苗前后的抗体滴度。
JAMA. 2021 Dec 7;326(21):2203-2204. doi: 10.1001/jama.2021.19885.
7
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.mRNA 疫苗可诱导对 SARS-CoV-2 及其关注变种的持久免疫记忆。
Science. 2021 Dec 3;374(6572):abm0829. doi: 10.1126/science.abm0829.
8
Adaptive immunity to SARS-CoV-2 and COVID-19.对 SARS-CoV-2 和 COVID-19 的适应性免疫。
Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12.
Zotero 插件